Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-141.2	-122.53	-89.62	-51.32	-38.05
Depreciation & Amortization	1.68	1	0.32	0.28	0.07
Other Amortization	-	-	-	-	0.05
Loss (Gain) From Sale of Assets	-10.25	-	-	-	-
Loss (Gain) From Sale of Investments	-15.59	-18.47	-5.98	-0.91	0.03
Stock-Based Compensation	28.99	18.79	8.19	2.51	1.49
Other Operating Activities	2.21	1.6	0.63	0.35	0.19
Change in Accounts Payable	4.77	3.31	-0.86	2.15	1.9
Change in Other Net Operating Assets	-92.81	-0.34	7.83	0.82	2.17
Operating Cash Flow	-222.2	-116.64	-79.49	-46.12	-32.16
Capital Expenditures	-3.61	-1.29	-2.17	-0.16	-1.21
Sale of Property, Plant & Equipment	10.25	-	-	-	-
Investment in Securities	83.16	-357.62	-266.18	-61.95	19.07
Investing Cash Flow	89.8	-358.91	-268.34	-62.11	17.86
Issuance of Common Stock	765.15	517.06	473.1	0.03	0.01
Repurchase of Common Stock	-0.62	-	-	-0.01	-
Other Financing Activities	-2.02	-1.8	-21.57	-2.51	3.24
Financing Cash Flow	762.52	515.26	451.53	29.01	103.25
Net Cash Flow	630.11	39.72	103.7	-79.21	88.95
Free Cash Flow	-225.81	-117.93	-81.66	-46.28	-33.37
Free Cash Flow Per Share	-3.81	-2.24	-2.22	-14.48	-12.30
Levered Free Cash Flow	-180.03	-70.78	-51.38	-26.08	-18.79
Unlevered Free Cash Flow	-180.03	-70.78	-51.38	-26.08	-18.76
Change in Working Capital	-88.04	2.96	6.97	2.97	4.06

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q